A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow-Up.

Autor: Talekar AL; Department of Pedodontics and Preventive Dentistry, M.A. Rangoonwala College of Dental Sciences and Research Centre, Pune, Maharashtra, India.; Private Practitioner at Kids Dental Corner Camp, Pune, Maharashtra, India., Musale PK; SMBT Institute of Dental Science and Research, Nasik, Maharashtra, India.; Department of Pedodontics and Preventive Dentistry, Private Practitioner at Little Ones Big Smiles, Pune, Maharashtra, India., Chaudhari GS; Department of Pedodontics and Preventive Dentistry, M.A. Rangoonwala College of Dental Sciences and Research Centre, Pune, Maharashtra, India.; Private Practitioner at Kids Dental Corner Camp, Pune, Maharashtra, India., Silotry TMH; G. D. Pol Foundation's YMT Dental College, Navi Mumbai, Maharashtra, India., Waggoner WF; Private Practitioner at Pediatric Dental Care Associates, Las Vegas, Nevada, USA.
Jazyk: angličtina
Zdroj: International journal of paediatric dentistry [Int J Paediatr Dent] 2024 Dec 06. Date of Electronic Publication: 2024 Dec 06.
DOI: 10.1111/ipd.13288
Abstrakt: Background: In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth.
Aims: To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months.
Design: Children aged 4-9 years, with deep dentinal caries (ICDAS 4-6) in primary molars, having no history of spontaneous pain or signs of non-vitality were included in the study. Following clinical and radiographic evaluation 117 primary molars diagnosed as having reversible pulpitis received pulpotomy treatment, after randomly being assigned into three groups based on the bioceramic calcium silicate medicament used: a pre-mixed syringe-loaded MTA putty (NeoPUTTY); a traditional powder-liquid hand mix MTA material (NeoMTA Plus), and a precapsulated, trituration mixed material (Biodentine). Clinical and radiographic evaluation was done at 6, 12, 18 and 24 months.
Results: The cumulative clinical and radiographic success for NeoPUTTY was 92%, NeoMTA Plus 97% and for Biodentine 95% and 89%, respectively, after 24 months follow-up.
Conclusion: The clinical and radiographic success rates of all three bioceramic calcium silicate cements were found to be high, with no significant differences over a period of 24 months.
Trial Registration: Clinical trial registration number: CTRI/2021/03/031655.
(© 2024 BSPD, IAPD and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: